It's exciting to see what 2017 has in store for the scientific community. There are predictions that there will be more breakthroughs on the study of space, climate change and biotechnology. Gizmodo reported that there will be more news about space exploration especially when the Cassini-Huygens mission to Saturn ends its course. In April next year, it will begin its "Grand Finale," which is a series of close passes between the planet and its rings....
.UNIVERSITYHERALD
READ MORE
|
BioNTech has raised $325 million (289 million Euros) in a private fundraising round. The series B positions the immuno-oncology player to advance its multidrug clinical pipeline and grow its manufacturing footprint. Mainz, Germany-based BioNTech operated for a decade without raising a headline-grabbing round, opting instead to run on money from its billionaire majority owners and partnership fees, such as the $310 million in upfront and near-term milestones put up by Genentech. That changed earl...
READ MORE
|
Bayer is paying Arvinas $17.5 million (€15.5 million) upfront to develop protein-degrading treatments for cardiovascular, oncological and gynecological diseases. The partners will apply Arvinas targeted protein degrader technology to targets selected by Bayer.Arvinas moved the first targeted protein degrader into human testing earlier this year, beating rival biotechs and Big Pharmas including C4 Therapeutics, Kymera Therapeutics, Merck and Novartis to that milestone. The number of co...
FIERCEBIOTECH
READ MORE
|
UMass Lowell already has a strong program in advanced manufacturing, anchored by the Massachusetts BioManufacturing Center on campus. Now, the university's program will get even stronger as it joins a public-private partnership to develop new advanced manufacturing technologies and train a skilled workforce. Massachusetts has been named a partner in the nation's first manufacturing innovation institute in biopharmaceutical manufacturing, and UMass Lowell is one of five universities suppo...
LOWELL SUN
READ MORE
|
IO Biotech, based in Copenhagen, has entered an agreement with Merck (the US one) to enter a Phase I/II trial for treating lung cancer with IO’s immune modulator, IO102, and Merck’s checkpoint inhibitor Keytruda. The Merck collaboration marks an important step for the young Danish company in advancing its pipeline of cancer drugs....
LABIOTECH.EU
READ MORE
|
Current thinking about Alzheimer's disease is that neuronal cell death in the brain is to blame for the cognitive havoc caused by the disease. But a new study suggests that neuronal death may actually be a protective reaction against the disease. This could lead to a complete rethinking of therapeutic approaches to Alzheimer's. For the first time, scientists at the Champalimaud Centre for the Unknown (CCU) in Lisbon, Portugal, have shown that neuronal cell death in Alzheimer's diseas...
READ MORE
|